1. Kim SJ, Chung SY, Park BJ. Pharmacovigilance organization and activity of WHO-UMC. J Pharmacoepidemiol Risk Manag 2014;7:1-6.
2. International drug monitoring: the role of national centres: report of a WHO meeting. World Health Organ Tech Rep Ser 1972;498:1-25.
3. World Health Organization. The importance of pharmacovigilance: safety monitoring of medicinal products [Internet] Geneva: World Health Organization. 2002;cited 2019 Jen 18. Available from:
https://apps.who.int/medicinedocs/en/d/Js4893e/
4. Gomes ER, Demoly P. Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol 2005;5:309-316.
5. Yang MS, Ban GY, Kim MH, Lim KH, Kwon HS, Song WJ, Jung JW, Lee JM, Suh DI, Kwon JW, Kim SH, Shin YS, Kang HR, Kim TB, Lee BJ, Lee AY, Park HS, Cho SH. KAAACI Standardization Committee Report on the procedures and applications of the diagnostic tests for drug allergy. Allergy Asthma Respir Dis 2017;5:239-247.
6. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000;356:1255-1259.
7. Hartigan-Go KY, Wong JQ. Inclusion of therapeutic failures as adverse drug reactions. Side Eff Drugs Annu 2000;23:xxvii-xxxiii.
8. Weiss ME, Adkinson NF. Immediate hypersensitivity reactions to penicillin and related antibiotics. Clin Allergy 1988;18:515-540.
10. Demoly P, Adkinson NF, Brockow K, Castells M, Chiriac AM, Greenberger PA, Khan DA, Lang DM, Park HS, Pichler W, Sanchez-Borges M, Shiohara T, Thong BY. International consensus on drug allergy. Allergy 2014;69:420-437.
11. Yang MS, Jung JW, Kang HR. Severe cutaneous adverse reaction. Korean J Med 2014;87:665-674.
12. Jang IJ. Introduction to clinical pharmacogenetics. J Korean Soc Clin Pharmacol Ther 2007;15:5-19.
13. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005;352:2211-2221.
14. Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006;368:704.
16. Park WB, Choe PG, Song KH, Lee S, Jang HC, Jeon JH, Park SW, Park MH, Oh MD, Choe KW. Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir? Clin Infect Dis 2009;48:365-367.
17. Jung JW, Song WJ, Kim YS, Joo KW, Lee KW, Kim SH, Park HY, Chang YS, Sho SH, Min KU, Kang HR. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Nephrol Dial Transplant 2011;26:3567-3572.
18. Jung JW, Kim DK, Park HW, Oh KH, Joo KW, Kim YS, Ahn C, Lee KW, Cho SH, Min KU, Kang HR. An effective strategy to prevent allopurinol-induced hypersensitivity by HLA typing. Genet Med 2015;17:807-814.
19. Kim SH, Kim M, Lee KW, Kim SH, Kang HR, Park HW, Jee YK. HLA-B
*5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Pharmacogenomics 2010;11:879-884.
20. Kim S, Yun J, Kang DY, Park HJ, Jo EJ, Jung JW, Park HK, Park JW, Jee YK, Kang HR, Lee JM. Carbonic anhydrase inhibitor-induced Stevens-Johnson syndrome/toxic epidermal necrolysis leads to extensive cutaneous involvement. J Allergy Clin Immunol Pract 2019;05. 22. 10.1016/j.jaip.2019.05.010. [Epub].
21. Choi NK, Park BJ. Adverse drug reaction surveillance system in Korea. J Prev Med Public Health 2007;40:278-284.
22. Yang MS. Relief system for adverse drug reactions in Korea. Korean J Med 2018;93:5-13.
23. Kim SJ, Kim JY, Song EH, Cho MJ, Lee KJ, Jung SY, Han SY. Introduction of current status of the adverse drug reaction relief system in Korea, Japan and Taiwan. J Pharmacoepidemiol Risk Manag 2019;11:1-8.